Table 3 Treatment-related adverse events (TRAEs)

From: Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Preferred term, n (%)

RET fusion–positive solid tumors (n = 29)a

All grades

Grade ≥3

Patients with TRAEs

25 (86)

20 (69)

 Increased AST

11 (38)

3 (10)

 Increased ALT

10 (34)

2 (7)

 Neutropenia

10 (34)

9 (31)

 Anemia

9 (31)

4 (14)

 Constipation

7 (24)

0

 Decreased white blood cell count

6 (21)

2 (7)

 Thrombocytopenia

5 (17)

2 (7)

 Hypertension

5 (17)

2 (7)

 Asthenia

5 (17)

0

  1. TRAEs that occurred in ≥15% of patients in the safety population (n = 29), which were graded according to the Common Terminology Criteria for Adverse Events version 4.03, with terms pooled. aEnrollment and data cutoff date as of 18 October 2021.
Back to article page